pharmaphorum
DECEMBER 15, 2022
Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE. The NHS should make Ofev available within 90 days of the announcement by NICE, which means in mid-March 2023.
European Pharmaceutical Review
MARCH 11, 2024
In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. 3 But that paradigm is rapidly changing. Internet] 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 19, 2022
FDA highlighted that over three quarters of new patents in the Orange Book between 2005 and 2015 were assigned to existing drugs. 10 There is a fear that such practices discourage innovative approaches, impacting on patient welfare. Finally, product hopping is another tactic for hindering generic entry into the market. 2020-02-24.
European Pharmaceutical Review
FEBRUARY 14, 2024
Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. 2015; 69(1):381–403 5. Despite the recent focus, LBPs of defined compositions are yet to be approved for commercialisation for any target indication. Leveraging Quorum Sensing to Manipulate Microbial Dynamics. 2021; 19:100306 4.
European Pharmaceutical Review
JANUARY 18, 2024
The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. Comparatively, in 2015, GlobalData’s research expected that sales of therapies for Gaucher disease will reach $1.16 percent from $3.2 billion in 2022 to $4.1 billion in 2032. percent between 2022 and 2032.
pharmaphorum
JANUARY 16, 2023
Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. More approvals, in larger patient population conditions will elevate the ongoing discussion of how to pay for these therapies.
Pharmaceutical Technology
OCTOBER 10, 2022
The company is aiming to enrol the first patient in the ALETTA Phase III trial in Q1 or Q2 of 2023, says Dr. Jan van der Mooren, Freya’s chief medical officer (CMO). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed. But these treatments have their own limits.
Expert insights. Personalized for you.
101 
Let's personalize your content